Anifrolumab Malignancy and Serious Infections Study
← catalyst calendarNCT07000110 · readout in 1,929 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With IQVIA Pty Ltd.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
3,506estimated
Sites
4
Countries
Denmark, France, Germany +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-26 | actual | When the study began enrolling |
| Primary completion | 2031-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Intervention
- Drug: Anifrolumab — also filed as Saphnelo
Primary outcomes
what the primary-completion date above is the date OFMalignancies
measured Indexdate to November 2031
Serious infection
measured Indexdate to November 2027
Infections leading to hospitalisation
measured Index date to November 2027
Infection-related death
measured Indexdate to November 2027
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed